Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

J Donald Easton, Renato D Lopes, M Cecilia Bahit, Daniel M Wojdyla, Christopher B Granger, Lars Wallentin, Marco Alings, Shinya Goto, Basil S Lewis, Mårten Rosenqvist, Michael Hanna, Puneet Mohan, John H Alexander, Hans-Christoph Diener, ARISTOTLE Committees and Investigators, Christian Tobias Torp-Pedersen

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    260 Citationer (Scopus)

    Abstract

    In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA.
    OriginalsprogEngelsk
    TidsskriftThe Lancet Neurology
    Vol/bind11
    Udgave nummer6
    Sider (fra-til)503-11
    Antal sider9
    ISSN1474-4422
    DOI
    StatusUdgivet - jun. 2012

    Citationsformater